{"id":"W4389241514","doi":"10.1158/1535-7163.targ-23-b130","title":"Abstract B130: Phase 1 study of Zanidatamab Zovodotin (ZW49): Safety Profile and Recommended Dose (RD) in patients with Human Epidermal Growth Factor 2 (HER2)-positive solid cancers","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Zymeworks (Canada); McGill University; Jewish General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Tolerability; Medicine; Trastuzumab; Pharmacokinetics; Internal medicine; Population; Cancer; Pharmacology; Adverse effect; Antibody-drug conjugate; Oncology; Breast cancer; Antibody; Gastroenterology; Immunology; Monoclonal antibody","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008169634,0.0007835844,0.0008941768,0.0002785196,0.0002141061,0.0005639048,0.0004378145,0.0005293306,0.002862718],"category_scores_gemma":[0.0005604159,0.0003413981,0.0004795987,0.0002621223,0.0004145065,0.0004460574,0.0002514995,0.001764747,0.0006363498],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007242137,"about_ca_system_score_gemma":0.001100749,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001052895,"about_ca_topic_score_gemma":0.00247711,"domain_scores_codex":[0.9997662,0.0001090558,0.00001191889,0.00003681959,0.00003917822,0.00003683472],"domain_scores_gemma":[0.9997544,0.00004140613,0.0000704397,0.00001696071,0.00001705252,0.00009982621],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3421125,0.04831357,0.024698,0.001007485,0.0008146818,0.0006498283,0.0004220651,0.006147295,0.3441686,0.0007237726,0.01037312,0.2205691],"study_design_scores_gemma":[0.223738,0.6316881,0.07862903,0.0000743191,0.0006331598,0.001398091,0.0001414496,0.005038651,0.04373886,0.0005096051,0.01434758,0.00006330285],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9922312,0.001473055,0.000696902,0.0002361882,0.00002676315,0.00130225,0.001894641,0.00007115637,0.00206778],"genre_scores_gemma":[0.9885462,0.001346441,0.002057616,0.0004272994,0.00006353503,0.0007672557,0.003677061,0.00003825984,0.003076376],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002862718,"threshold_uncertainty_score":0.009576738,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04065824037030909,"score_gpt":0.3679402747168807,"score_spread":0.3272820343465717,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}